Xenetic Biosciences Statistics
Total Valuation
XBIO has a market cap or net worth of $3.93 million. The enterprise value is -$2.23 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XBIO has 1.54 million shares outstanding. The number of shares has increased by 0.86% in one year.
| Current Share Class | 1.54M |
| Shares Outstanding | 1.54M |
| Shares Change (YoY) | +0.86% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 7.28% |
| Owned by Institutions (%) | 6.44% |
| Float | 1.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.57 |
| Forward PS | 2.83 |
| PB Ratio | 0.65 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.37
| Current Ratio | 7.37 |
| Quick Ratio | 6.89 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.12% and return on invested capital (ROIC) is -33.26%.
| Return on Equity (ROE) | -50.12% |
| Return on Assets (ROA) | -30.02% |
| Return on Invested Capital (ROIC) | -33.26% |
| Return on Capital Employed (ROCE) | -69.99% |
| Revenue Per Employee | $1.25M |
| Profits Per Employee | -$1.98M |
| Employee Count | 2 |
| Asset Turnover | 0.29 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.90% in the last 52 weeks. The beta is 2.31, so XBIO's price volatility has been higher than the market average.
| Beta (5Y) | 2.31 |
| 52-Week Price Change | -35.90% |
| 50-Day Moving Average | 3.30 |
| 200-Day Moving Average | 3.84 |
| Relative Strength Index (RSI) | 40.49 |
| Average Volume (20 Days) | 9,771 |
Short Selling Information
The latest short interest is 3,470, so 0.23% of the outstanding shares have been sold short.
| Short Interest | 3,470 |
| Short Previous Month | 4,534 |
| Short % of Shares Out | 0.23% |
| Short % of Float | 0.29% |
| Short Ratio (days to cover) | 0.49 |
Income Statement
In the last 12 months, XBIO had revenue of $2.50 million and -$3.96 million in losses. Loss per share was -$2.57.
| Revenue | 2.50M |
| Gross Profit | 2.50M |
| Operating Income | -4.20M |
| Pretax Income | -4.47M |
| Net Income | -3.96M |
| EBITDA | n/a |
| EBIT | -4.20M |
| Loss Per Share | -$2.57 |
Full Income StatementBalance Sheet
The company has $6.17 million in cash and n/a in debt, giving a net cash position of $6.17 million or $4.00 per share.
| Cash & Cash Equivalents | 6.17M |
| Total Debt | n/a |
| Net Cash | 6.17M |
| Net Cash Per Share | $4.00 |
| Equity (Book Value) | 6.01M |
| Book Value Per Share | 3.89 |
| Working Capital | 5.69M |
Full Balance SheetCash Flow
| Operating Cash Flow | -2.82M |
| Capital Expenditures | n/a |
| Free Cash Flow | -2.82M |
| FCF Per Share | -$1.83 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -168.16% and -158.39%.
| Gross Margin | 100.00% |
| Operating Margin | -168.16% |
| Pretax Margin | -158.39% |
| Profit Margin | -158.39% |
| EBITDA Margin | n/a |
| EBIT Margin | -168.16% |
| FCF Margin | n/a |